Surgical guidance specialist Endomag has won a British Business Innovation Award from the Institute of Physics, the professional and learned society for physics in the UK and Ireland, encouraging innovation, growth and productivity in business.
As one of only six winners receiving an IOP Business Innovation Award this year, the award celebrates Endomag’s success in developing and delivering significant impact with a system that uses magnetism for minimally invasive surgical guidance, helping surgeons locate early-stage and impalpable tumours, predominantly in breast cancer surgery. Through its experience in engineering development and its detailed understanding of the physics of magnetic sensing technology, Endomag has developed a system that eliminates the need for radioactive materials in surgery, making it a safer, more comfortable, convenient and efficient option over alternative techniques such as radiation or wire-guided excision biopsies.
Core to Endomag’s innovation is the company’s ultra-sensitive magnetic detection probe, Sentimag, which was first applied in 2013 and has been demonstrated to be as accurate as the current gold standards in numerous clinical trials. Sentimag is used by hospitals in more than 30 countries in combination with the company’s innovative ‘locating’ and ‘tracing’ products, Magseed and Magtrace, respectively. These products help to guide surgeons to early-stage breast cancers, aiming to maximise the amount of healthy tissue left behind after surgery and determine whether the cancer has spread.
The Business Innovation Award recognises and celebrates small, medium and large companies that have excelled in innovation, delivering significant economic and/or societal impact through the application of physics. Endomag was presented with the award by Professor Dame Julia Higgins on October 16 of this year.
Latest from Tom Mulligan
- EVENT PREVIEW: CPhI North America opens next week!
- NEW BUSINESS: SK biotek and AMPAC Fine Chemicals have ambitious CDMO plans
- NEW TECHNOLOGY: Polyplus-transfection develops GMP-grade therapeutic virus reagent
- Mogrify raises $3.7 million seed funding to support direct cellular conversion for cell therapy
- Owlstone Medical partners with Shanghai Renji Hospital to pioneer Breath Biopsy lung cancer trial
- Chemspace and LabNetwork collaborate to extend access to chemical databases
- TECHNOLOGY UPDATE: Catalent invests over $27 million to commercialise next-generation ODT Zydis Ultra
- SGS reports successful Phase 2 results for novel influenza vaccine, validating its H3N2 A/Belgium challenge agent
- NEW TECHNOLOGY: Horizon Discovery and Rutgers University develop new gene editing approach: ‘base editing’
- EVENT REVIEW: Busy sessions at BIO-Europe Spring!